2157 Effects of Compound V on Pulmonary Fibrosis Model

Thursday, 15 October 2015
Hall D1 Foyer (Floor 3) (Coex Convention Center)

Chuang/Yao Ming , Biotechnology, National Formosa University, Yunlin, Taiwan

Ye/Yi Ling, MD , Biotechnology, National Formosa University, Yunlin, Taiwan

Jiu-Yao Wang, MD, PhD , Allergy and Clinical Immunology Research Center, National Cheng Kung University Hospital, Tainan, Taiwan

Jiu-Yao Wang, MD, PhD , Allergy and Clinical Immunology Research Center, National Cheng Kung University Hospital, Tainan, Taiwan

Background: Pulmonary fibrosis is a lung disease which is hardly to cure and has a high mortality rate. Recently, the studies suggested that TGF-β plays a central role in the pathogenesis of pulmonary fibrosis. Compound V, isolated from natural source, is used as theantioxidant, however, we find this compound can suppress the expression of collagen on TGF-β treated lung fibroblast cell line. Therefore, we would like to realize the influence of this compound on lung fibrosis animal model.   Methods: To establish pulmonary fibrosis of animal model, we treat mice with bleomycin on day 0 by intratracheal injection, so as to treat compound V by oral daily from day -7 to day 7.Afterwards, we collected mice bronchoalveolar lavage fluids, spleen and lung section and observed the effect of compound V on pulmonary fibrosis of animal model through ELISA, histology and SCIREQ(the machine which detect mice lung function).   Results: Compound V can improve lung fibrosis in physiology significantly by SCIREQ. The collagen expression in lung sections also decreased apparently.   Conclusions: These findings indicate that compound V can reduce collagen expression on bleomycin-induced pulmonary fibrosis animal model. We will further figure out the mechanism of compound V on pulmonary fibrosis.